79712-53-1|Tazifylline HCl|7-(2-hydroxy-3-(4-(3-(phenylthio)propyl)piperazin-1-yl)propyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione dihydrochloride|-范德生物科技公司

Tazifylline HCl

NMR下载 COA and HPLC MSDS下载
names：
7-(2-hydroxy-3-(4-(3-(phenylthio)propyl)piperazin-1-yl)propyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione dihydrochloride
CAS号：
79712-53-1
MDL Number：
MF(分子式)： C23H34Cl2N6O3S MW(分子量)： 545.52
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	7-(2-hydroxy-3-(4-(3-(phenylthio)propyl)piperazin-1-yl)propyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione dihydrochloride
英文别名	Tazifylline hydrochloride; Tazifylline HCl; LN 2974; RS-49014; RS 49014; RS49014; LN2974; LN-2974;
CAS号	79712-53-1
SMILES	O=C(N1C)N(C)C2=C(N(CC(O)CN3CCN(CCCSC4=CC=CC=C4)CC3)C=N2)C1=O.[H]Cl.[H]Cl
Inchi	InChI=1S/C23H32N6O3S.2ClH/c1-25-21-20(22(31)26(2)23(25)32)29(17-24-21)16-18(30)15-28-12-10-27(11-13-28)9-6-14-33-19-7-4-3-5-8-19;;/h3-5,7-8,17-18,30H,6,9-16H2,1-2H3;2*1H
InchiKey	HFYFNZKRWQJSLF-UHFFFAOYSA-N
分子式 Formula	C23H34Cl2N6O3S
分子量 Molecular Weight	545.52
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Tazifylline HCl(CAS:79712-53-1):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Tazifylline HCl is an antihistaminic agent.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Poizot A, Dumez D, Ferrandon P, Lefournier C, Michel A, Armstrong JM. Animal pharmacology of the selective histamine H1-receptor antagonist tazifylline. Arzneimittelforschung. 1986 Apr;36(4):695-702. PubMed PMID: 2424463.

[2]Ring J, Galosi A, Harlow BJ, Reuter CA, Bieber T, Ruzicka T, Yee KF. Antiallergic effects of the new histamine H1-receptor antagonist tazifylline in healthy atopic and non-atopic subjects. Arzneimittelforschung. 1988 Feb;38(2):308-11. PubMed PMID: 2897197.

[3] Bruno R, Jullien I, Auger J, Iliadis A, Dow R, McEwen J, Cano JP, Pinhas H. Multiple-dose pharmacokinetics of the new H1-receptor antagonist tazifylline in healthy volunteers. Biopharm Drug Dispos. 1989 Jan-Feb;10(1):115-9. PubMed PMID: 2564283.

[4] Kiviranta K, Stenius-Aarniala B, Reuter C, Harlow B, Scott J. The reducing effects of tazifylline on histamine-induced bronchoconstriction in atopic asthmatics. Methods Find Exp Clin Pharmacol. 1989 Feb;11(2):119-21. PubMed PMID: 2565416.

[5] Nicholson AN, Stone BM. Antihistamines: impaired performance and the tendency to sleep. Eur J Clin Pharmacol. 1986;30(1):27-32. PubMed PMID: 3086105.

6: Savin JA, Dow R, Harlow BJ, Massey H, Yee KF. The effect of a new non-sedative H1-receptor antagonist (LN2974) on the itching and scratching of patients with atopic eczema. Clin Exp Dermatol. 1986 Nov;11(6):600-2. PubMed PMID: 2889550.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开